Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

studies conducted with non-commercially available analog formulations, or trials conducted with insulin preparations that are no longer commercially available.

This human insulin analogue that comes in disposable pens prefilled with 1, 1.5, or 3 mL, dosed in 10-unit increments1 binds reversibly to albumin, which extends its half-life to around 7 days. Steady ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...

Various insulin regimens are used to treat patients with type 2 diabetes mellitus that is inadequately controlled by oral antidiabetic therapy. However, few studies have compared insulin regimens.

Today, Plantsulin blends this century-old discovery with modern scientific validation to offer a fast, convenient “whole-body reboot” for maintaining optimal glucose levels. Unlike restrictive diets ...

This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...

Can long-acting insulin analogs help overcome the challenge of nocturnal hypoglycemia? On the basis of this review of clinical trial results, insulin detemir or insulin glargine may be the best ...